Immacolata Brigida

Immacolata Brigida

Auto-generated profile, based on publicly available information

Immacolata Brigida

Pathogenesis and therapy of primary immunodeficiencies Unit San Raffaele Telethon Institute for Gene Therapy Sr‐TIGET IRCCS San Raffaele Hospital Via Olgettina 60 Milan 20132 Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2009 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
AAAlessandro Aiuti
Alessandro Aiuti
FCFederica Cattaneo
Federica Cattaneo
SGStefania Galimberti
Stefania Galimberti
UBUlrike Benninghoff
Ulrike Benninghoff
BCBarbara Cassani
Barbara Cassani
MRMaria-Grazia Roncarolo
Maria-Grazia Roncarolo
We investigated the long-term outcome of gene therapy for severe combined immunodeficiency (SCID) due to the lack of adenosine deaminase (ADA), a fatal disorder of purine metabolism and immunodeficiency.

1 March 2013 in Clinical Immunology
Verified
Journal Article
Open access
KGKevin Goudy
Kevin Goudy
DADidem Aydin
Didem Aydin
FBFederica Barzaghi
Federica Barzaghi
Eleonora GambineriEleonora Gambineri
Eleonora Gambineri
MVMarina Vignoli
Marina Vignoli
RBRosa Bacchetta
Rosa Bacchetta
Cell-surface CD25 expression is critical for maintaining immune function and homeostasis. As in few reported cases, CD25 deficiency manifests with severe autoimmune enteritis and viral infections. To dissect the underlying immunological mechanisms driving these symptoms, we analyzed the regulatory and effector T cell functions in a CD25 deficient patient harboring a novel IL2RA mutation. Pronounced lymphoproliferation, mainly of the CD8(+) T cells, was detected together with an increase in T cell activation markers and elevated serum cytokines. However, Ag-specific responses were impaired in vivo and in vitro. Activated CD8(+)STAT5(+) T cells with lytic potential infiltrated the skin, even though FOXP3(+) Tregs were present and maintained a higher capacity to respond to IL-2 compared to other T-cell subsets. Thus, the complex pathogenesis of CD25 deficiency provides invaluable insight into the role of IL2/IL-2RA-dependent regulation in autoimmunity and inflammatory diseases.

1 January 2012 in Frontiers in Immunology
Verified
Journal Article
Open access
ASAisha Vanessa Sauer
Aisha Vanessa Sauer
IBImmacolata Brigida
Immacolata Brigida
NCNicola Carriglio
Nicola Carriglio
AAAlessandro Aiuti
Alessandro Aiuti
Genetic defects in the adenosine deaminase (ADA) gene are among the most common causes for severe combined immunodeficiency (SCID). ADA-SCID patients suffer from lymphopenia, severely impaired cellular and humoral immunity, failure to thrive and recurrent infections. Currently available therapeutic options for this otherwise fatal disorder include bone marrow transplantation (BMT), enzyme replacement therapy with bovine ADA (PEG-ADA) or hematopoietic stem cell gene therapy (HSC-GT). Although varying degrees of immune reconstitution can be achieved by these treatments, breakdown of tolerance is a major concern in ADA-SCID. Immune dysregulation such as autoimmune hypothyroidism, diabetes mellitus, hemolytic anemia, and immune thrombocytopenia are frequently observed in milder forms of the disease. However, several reports document similar complications also in patients on long-term PEG-ADA and after BMT or GT treatment. A skewed repertoire and decreased immune functions have been implicated in autoimmunity observed in certain B-cell and/or T-cell immunodeficiencies, but it remains unclear to what extent specific mechanisms of tolerance are affected in ADA deficiency. Herein we provide an overview about ADA-SCID and the autoimmune manifestations reported in these patients before and after treatment. We also assess the value of the ADA-deficient mouse model as a useful tool to study both immune and metabolic disease mechanisms. With focus on regulatory T and B cells we discuss the lymphocyte subpopulations particularly prone to contribute to the loss of self-tolerance and onset of autoimmunity in ADA deficiency. Moreover we address which aspects of immune dysregulation are specifically related to alterations in purine metabolism caused by the lack of ADA and the subsequent accumulation of metabolites with immunomodulatory properties.

29 November 2018 in Blood
Verified
Journal Article
Open access
PDF file
IBImmacolata Brigida
Immacolata Brigida
MZMatteo Zoccolillo
Matteo Zoccolillo
MCMaria Pia Cicalese
Maria Pia Cicalese
LPLaurène Pfajfer
Laurène Pfajfer
FBFederica Barzaghi
Federica Barzaghi
AAAlessandro Aiuti
Alessandro Aiuti
ARPC1B is a key factor for the assembly and maintenance of the ARP2/3 complex that is involved in actin branching from an existing filament. Germline biallelic mutations in ARPC1B have been recently described in 6 patients with clinical features of combined immunodeficiency (CID), whose neutrophils and platelets but not T lymphocytes were studied. We hypothesized that ARPC1B deficiency may also lead to cytoskeleton and functional defects in T cells. We have identified biallelic mutations in ARPC1B in 6 unrelated patients with early onset disease characterized by severe infections, autoimmune manifestations, and thrombocytopenia. Immunological features included T-cell lymphopenia, low numbers of naïve T cells, and hyper–immunoglobulin E. Alteration in ARPC1B protein structure led to absent/low expression by flow cytometry and confocal microscopy. This molecular defect was associated with the inability of patient-derived T cells to extend an actin-rich lamellipodia upon T-cell receptor (TCR) stimulation and to assemble an immunological synapse. ARPC1B-deficient T cells additionally displayed impaired TCR-mediated proliferation and SDF1-α−directed migration. Gene transfer of ARPC1B in patients’ T cells using a lentiviral vector restored both ARPC1B expression and T-cell proliferation in vitro. In 2 of the patients, in vivo somatic reversion restored ARPC1B expression in a fraction of lymphocytes and was associated with a skewed TCR repertoire. In 1 revertant patient, memory CD8+ T cells expressing normal levels of ARPC1B displayed improved T-cell migration. Inherited ARPC1B deficiency therefore alters T-cell cytoskeletal dynamics and functions, contributing to the clinical features of CID.

9 February 2012 in Blood
Verified
Journal Article
Closed access
PDF file
ASAisha V. Sauer
Aisha V. Sauer
IBImmacolata Brigida
Immacolata Brigida
NCNicola Carriglio
Nicola Carriglio
RHRaisa Jofra Hernandez
Raisa Jofra Hernandez
SSSamantha Scaramuzza
Samantha Scaramuzza
AAAlessandro Aiuti
Alessandro Aiuti
Adenosine acts as anti-inflammatory mediator on the immune system and has been described in regulatory T cell (Treg)–mediated suppression. In the absence of adenosine deaminase (ADA), adenosine and other purine metabolites accumulate, leading to severe immunodeficiency with recurrent infections (ADA-SCID). Particularly ADA-deficient patients with late-onset forms and after enzyme replacement therapy (PEG-ADA) are known to manifest immune dysregulation. Herein we provide evidence that alterations in the purine metabolism interfere with Treg function, thereby contributing to autoimmune manifestations in ADA deficiency. Tregs isolated from PEG-ADA–treated patients are reduced in number and show decreased suppressive activity, whereas they are corrected after gene therapy. Untreated murine ADA−/− Tregs show alterations in the plasma membrane CD39/CD73 ectonucleotidase machinery and limited suppressive activity via extracellular adenosine. PEG-ADA–treated mice developed multiple autoantibodies and hypothyroidism in contrast to mice treated with bone marrow transplantation or gene therapy. Tregs isolated from PEG-ADA–treated mice lacked suppressive activity, suggesting that this treatment interferes with Treg functionality. The alterations in the CD39/CD73 adenosinergic machinery and loss of function in ADA-deficient Tregs provide new insights into a predisposition to autoimmunity and the underlying mechanisms causing defective peripheral tolerance in ADA-SCID. Trials were registered at www.clinicaltrials.gov as NCT00598481/NCT00599781.

17 January 2011 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
LBLuca Biasco
Luca Biasco
AAAlessandro Ambrosi
Alessandro Ambrosi
DPDanilo Pellin
Danilo Pellin
CBCynthia Bartholomae
Cynthia Bartholomae
IBImmacolata Brigida
Immacolata Brigida
AAAlessandro Aiuti
Alessandro Aiuti
The analysis of genomic distribution of retroviral vectors is a powerful tool to monitor ‘vector‐on‐host’ effects in gene therapy (GT) trials but also provides crucial information about ‘host‐on‐vector’ influences based on the target cell genetic and epigenetic state. We had the unique occasion to compare the insertional profile of the same therapeutic moloney murine leukemia virus (MLV) vector in the context of the adenosine deaminase‐severe combined immunodeficiency (ADA‐SCID) genetic background in two GT trials based on infusions of transduced mature lymphocytes (peripheral blood lymphocytes, PBL) or a single infusion of haematopoietic stem/progenitor cells (HSC). We found that vector insertions are cell‐specific according to the differential expression profile of target cells, favouring, in PBL‐GT, genes involved in immune system and T‐cell functions/pathways as well as T‐cell DNase hypersensitive sites, differently from HSC‐GT. Chromatin conformations and histone modifications influenced integration preferences but we discovered that only H3K27me3 was cell‐specifically disfavoured, thus representing a key epigenetic determinant of cell‐type dependent insertion distribution. Our study shows that MLV vector insertional profile is cell‐specific according to the genetic/chromatin state of the target cell both in vitro and in vivo in patients several years after GT. See accompanying Closeup by Baum DOI: http://dx.doi.org/10.1002/emmm.201000110.